Bayer in frame to win first EU nod for high-precision cancer drug

Europe's drug regulator has recommended approving Bayer's Vitrakvi, putting the medicine on track to become the first in Europe to tackle tumours with a specific genetic mutation regardless of where in the body the disease started.